McClurg, D; Booth, L; Herrero-Fresneda, I. “Safety and Efficacy of Intermittent Colonic Exoperistalsis Device to Treat Chronic Constipation: A Prospective Multicentric Clinical Trial”, Clinical and Translational Gastroenterology: December 2020 – Volume 11
International Multicenter Clinical Trial
N=92 adult patients suffering from chronic constipation due to neurogenic bowel dysfunction or idiopathic causes with high component of pelvic floor disorders, used the medical device MOWOOT daily for 20 min over 4 weeks. Adherence to treatment was ≥95%. There were only 8.7% mild to moderate adverse events. Using the device significantly increased the number of complete bowel movements/week (V2-V1=1,8 (2.7) p=<0.0001); reduced the symptoms of chronic constipation (KESS score V2-V1=-3.9(5.0), p<0.0001), improved quality of life (PAC-QoL V2-V1=-0.7(0.8), p<0.0001) with a high number of responders (72,2% for bowel movements; 77,4% for constipation symptoms; 81% for Quality of life).
Considering safety, adherence, and efficacy being demonstrated, the results favor the use of MOWOOT to treat chronic constipation.
I.Herrero-Fresneda. “Intermittent Colonic Exoperistalsis Device for the Treatment of Chronic Constipation in Spinal Cord Injured Patients. A long-term evaluation in Home Care use.” AS-UEG-2021-00690 United European Gastroenterology Week,, 3-5 Oct 2021
Data resulted from anonymous, structured feedback from N=47 patients who were using MOWOOT-II-system at home in their daily routine for long-term to treat their severe chronic constipation (neurogenic bowel, idiopathic, and colon pathologies). There were only 6 low to moderate adverse events without any serious one. The number of bowel movements increased from 1 every 3 days to 1 every 1-2 days; the time spent per evacuation was reduced in 35 min; and all symptoms of discomfort associated to constipation were reduced. Laxatives and suppositories were reduced in 30% of cases. The patient satisfaction with bowel management increased to high or very high in 74% of cases. Usability and tolerability were rated in the highest categories by 82-93% of patients.
Significant improvements regarding the symptoms of chronic constipation along with a high tolerability and reductions of laxatives/suppositories could be achieved, demonstrating the benefit of the MOWOOT-II-System in the out-patient sector in the long-term use.
E Cèlia Jané, Georgia Romero, Immaculada Herrero-Fresneda. “Efectividad de la Exo-Peristalsis Intermitente de Colon con Mowoot como tratamiento del estreñimiento crónico” Congreso de la Sociedad Española de Fisioterapia en Pelvi-perineología”(SEFIP), Barcelona oct. 2019
E Cèlia Jané, Georgia Romero, Immaculada Herrero-Fresneda, Neus Ticó Falguera. “Efectividad de la Exo-Peristalsis Intermitente de Colon con MOWOOT como tratamiento del estreñimiento crónico” 58º Congreso de la Sociedad Española de Rehabilitación y Medicina Física (SERMEF), Palma Nov. 2020
N= 33 adult patients recruited at the specialized pelvic floor unit used MOWOOT daily for 20min over 14 days. N=17 patients completed the questionnaires. There was a significantly improvement in bowel movements per day (p=0.03), as well as in fecal consistency (p=0.009), and slight reduction in laxatives and suppositories. None reported adverse events.
The intermittent colonic exoperistalsis treatment with MOWOOT seems to be effective against constipation due to functional defecatory disorders.
I.Herrero-Fresneda. “Empowering Chronically Constipated Spinal Cord Injured patients by allowing them to take control over their bowel management”. 44th IHF World Hospital Congress, Barcelona 8-11 November 2021.
Data resulted from anonymous, structured feedback from N=28 patients who were using MOWOOT-II-system at home in their daily routine for the treatment of severe chronic constipation (neurogenic bowel and idiopathic). There were only 4 mild to moderate adverse events without any serious one. The number of bowel movements increased from 1 every 3 days to 1/day; the time spent per evacuation was reduced in 32 min; and all symptoms of discomfort associated to constipation were reduced. Laxatives and suppositories were reduced in 57% of cases. The patient satisfaction with bowel management increased to high or very high in 70% of cases. Usability and tolerability were rated in the highest categories by 89% of patients.
This evaluation demonstrated the benefit for the use of the MOWOOT-II-System in the out-patient sector.
Herrero-Fresneda, I; Klamburg , J; Benet, M; Calzada A; Wilhelms, M. ”Benefits of automated massage with MOWOOT on chronic constipation”. J Gastrointest Dig Syst 2018 Volume 8 DOI 10.4172 2161-069X-C1-064”
N= 15 (45 to 86yo), chronically constipated for >5yo due to idiopathic causes, not using the manual abdominal massage, received 15min automatic massage, once a day for 15 days, administered with the medical device MOWOOT. No adverse effects were reported. All the people described a pleasant relaxing sensation during the massage. Two people left the study. Three were excluded due to lack of adherence. Out of 10 people who completed the treatment, two were excluded due to anal dyssynergia. The final sample analyzed was n=8 (70.70±3.94yo). The results showed a clear increase in the average number of bowel movements per week (4.75±0.86 pre vs 6.5±1.09 post, P=0.0062); significant improvement in fecal consistency (Bristol 3.09±0.66 pre vs 5.02±0.41 post, P= 0.0335) and halving the defecation time (8.55±1.48 pre vs 4.59±0.74 min post, P=0.0036), resulting in a clear reduction in the constipation index (11.50±1.25 pre vs 8.25±.08 post, P=0.0001).
The specific massage of colon administered automatically with MOWOOT reduces the fecal consistency, increases the frequency of evacuations, and decreases the time of deposition, improving chronic constipation in adults.
N= 10 women (50 to 86yo), chronically constipated for >5yo due to idiopathic causes, w/o anal sphincter dyssynergia and not using the manual abdominal massage, received 15min automatic massage, once a day for 15 days, administered with the medical device MOWOOT. 2 people (50yo each) were excluded due to not compliance. There was not any reported adverse effect. Results showed a clear increase in the median number of depositions per week (from 4 to 6, P= 0.006); an amelioration in fecal consistency (from 3 to 5, Bristol P= 0.056), in min/deposition (from 7 to 3’8, P= 0.020) and in whole constipation score (CCCS from 12 to 8, P= 0.001). All patients reported comfortable sensation during the automated massage.
The colon-specific automatic massage improves the frequency of evacuations and fecal consistency ameliorating idiopathic chronic constipation in aged women.
(*) Content summarized by usMIMA SL